Serum soluble Fas levels in patients with systemic sclerosis;Ocena stȩżenia rozpuszczalnego białka Fas w surowicy chorych na twardzinȩ układowa̧

Postepy Dermatologii i Alergologii

Volumn 27, Issue 5, 2010, Pages 406-414

  Szymanek, Magdalena ^a   Chodorowska, Grazyna ^a   Kowal, Małgorzata ^a   Pietrzak, Aldona ^a   Miturska, Renata ^a   Krasowska, Dorota ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Apoptosis; Soluble Fas protein; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; COMPLEMENT COMPONENT C3; FAS ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD LEVEL; BLOOD VESSEL INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; ESOPHAGUS; FEMALE; HEART; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG; MEDICAL RESEARCH; REGULATORY MECHANISM; SYSTEMIC SCLEROSIS;

EID: 78649720075     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005; 26: 587-95.
2. Denton CP, Black CM. Scleroderma - clinical and pathological advances. Best Pract Res Clin Rheumatol 2004; 18: 271-90.
3. Haustein UF. Systemic sclerosis-scleroderma. Dermatol Online J 2002; 8: 3.
4. Latsi PI, Wells AU. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003; 15: 748-55.
5. Trojanowska M, Varga J. Molecular pathways as novel therapeutic targets in systemic sclerosis. Curr Opin Rheumatol 2007; 19: 568-73.
6. Gindzieńska-Sieśkiewicz E, Klimiuk PA, Kowal-Bielecka O, et al. Aspekty immunopatologiczne twardziny układowej. Pol Merk Lek 2005; 19: 800-3.
7. Haustein UF, Anderegg U. Pathophysiology of scleroderma: an update. J Eur Acad Dermatol Venereol 1998; 11: 1-8.
8. Gabrielli A, Svegliati S, Moroncini G, et al. Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Semin Immunopathol 2008; 30: 329-37.
9. Herrick AL, Matucci Cerinic M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001; 19: 4-8. (Pubitemid 32203838)
10. Jimenez SA, Artlett CM. Microchimerism and systemic sclerosis. Curr Opin Rheumatol 2005; 17: 86-90.
11. Riccieri V, Spadaro A, Fuksa L, et al. Specific oxidative stress parameters differently correlate with nailfold capillaroscopy changes and organ involvement in systemic sclerosis. Clin Rheumatol 2008; 27: 225-30.
12. Sfrent-Cornateanu R, Mihai C, Stoian I, et al. Antioxidant defense capacity in scleroderma patients. Clin Chem Lab Med 2008; 46: 836-41. (Pubitemid 351821630)
13. Kern P, Keilholz L, Forster C, et al. In vitro apoptosis in peripheral blood mononuclear cells induced by low-dose radiotherapy displays a discontinuous dose-dependence. Int J Radiat Biol 1999; 75: 995-1003.
14. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6.
15. Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature 2000; 407: 777-83.
16. Szpringer E, Lutnicki K. Znaczenie apoptozy w wybranych chorobach w dermatologii. Nowa Med 2002; 3: 24-32.
17. Arai H, Gordon D, Nabel EG, et al. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A 1997; 94: 13862-7.
18. Kavurma MM, Khachigian LM. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ 2003; 10: 36-44.
19. Mitrus I, Missol-Kolka E, Szala S. Geny proapoptotyczne w terapii genowej nowotworów. Współcz Onkol 2001; 5: 242-9.
20. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33: 29-55.
21. Watzlik A, Dufter C, Jung M, et al. Fas ligand gene-carrying adeno-5 AdE-asy viruses can be efficiently propagated in apoptosis-sensitive human embryonic retinoblast 911 cells. Gene Ther 2000; 7: 70-4.
22. Gu YS, Kong J, Cheema GS, et al. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008; 38: 132-60.
23. Yamamoto T, Nishioka K. Possible role of apoptosis in the pathogenesis of bleomycin induced scleroderma. J Invest Dermatol 2004; 122: 44-50. (Pubitemid 38114637)
24. Gilmore TD, Koedood M, Piffat KA, White DW. Rel/NF-kappaB/ IkappaB proteins and cancer. Oncogene 1996; 13: 1367-78.
25. Masi AT, Rodnan GP, Medsger TA, et al. Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
26. Wetzig T, Petri JB, Mittag M, et al. Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis. Arch Dermatol Res 1998; 290: 187-90.
27. Ateş A, Kinikli G, Turgay M, et al. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin Rheumatol 2004; 23: 421-5.
28. Cheng J, Zhou T, Liu C. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-62. (Pubitemid 24131584)
29. Dziankowska-Bartkowiak B, Waszczykowska E, Zalewska A, et al. Evaluation of caspase 1 and sFas serum levels in patients with systemic sclerosis: correlation with lung dysfunction, joint and bone involvement. Mediators Inflamm 2003; 12: 339-43. (Pubitemid 38161141)
30. Cipriani P, Fulminis A, Pingiotti E, et al. Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis. J Rheumatol 2006; 33: 2003-14.
31. Nozawa K, Kayagaki N, Tokano Y, et al. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 1997; 40: 1126-9.
32. Stummvoll GH, Aringer M, Smolen JS, et al. Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology (Oxford) 2000; 39: 1341-50.
33. Goel N, Ulrich DT, Clair WS, et al. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 1995; 38: 1738-43. (Pubitemid 26010274)
34. Tomokuni A, Aikoh T, Matsuki T, et al. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol 1997; 110: 303-9.
35. Chung L, Lin J, Furst DE, et al. Systemic and localized scleroderma. Clin Dermatol 2006; 24: 374-92.
36. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5. (Pubitemid 18073738)
37. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
38. Dziankowska-Bartkowiak B, Waszczykowska E, Sysa-Jȩdrzejowska A. Ocena zjawiska apoptozy u chorych na twardzinȩ układowa̧. Przegl Dermatol 2003; 1: 17-23. (Pubitemid 36378364)
39. Ingegnoli F, Trabattoni D, Saresella M, et al. Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis. Clin Immunol 2003; 108: 21-8.
40. Krasowska D. Patogeneza, kryteria rozpoznawania i klasyfikacja twardziny uk?adowej. Przegl Dermatol 2008; 95: 225-8.
41. Dziankowska-Bartkowiak B, Zalewska A, Sysa-Jedrzejowska A. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), solublereceptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients. Med Sci Monit 2004; 10: CR202-8.
42. Luzina IG, Papadimitriou JC, Anderson R, et al. Induction of prolonged infiltration of T lymphocytes and transient T lymphocyte- dependent collagen deposition in mouse lungs following adenoviral gene transfer of CCL18. Arthritis Rheum 2006; 54: 2643-55.
43. Kuwano K, Hagimoto N, Kawasaki M, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999; 104: 13-9.
44. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor beta 1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000; 43: 2230-9.
45. LeRoy EC. Increased collagen synthesis by scleroderma fibroblasts in vitro. J Clin Invest 1974; 54: 880-9.
46. Ahmed SS, Tan FK, Arnett FC, et al. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 2006; 54: 2250-62.
47. Mountz JD, Wu J, Cheng J, et al. Autoimmune disease: a problem of defective apoptosis. Arthritis Rheum 1994; 37: 1415-20. (Pubitemid 24337682)